A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France

Kaisa Taipale,1 Katherine B Winfree,2 Mark Boye,2 Mickael Basson,3 Ghassan Sleilaty,4 James Eaton,5 Rachel Evans,5 Christos Chouaid6 1Global Patient Outcomes and Real World Evidence International, Oy Eli Lilly Finland AB, Helsinki, Finland; 2Global Patient Outcomes and Real World Evidence, Eli Lilly...

Full description

Bibliographic Details
Main Authors:	Taipale K, Winfree KB, Boye M, Basson M, Sleilaty G, Eaton J, Evans R, Chouaid C
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-08-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	Advanced nonsquamous NSCLC Cost-effectiveness France Induction–maintenance Pemetrexed Quality-adjusted life-years
Online Access:	https://www.dovepress.com/a-cost-effectiveness-analysis-of-first-line-induction-and-maintenance--peer-reviewed-article-CEOR

Similar Items

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
by: Nicole F. Laslett, et al.
Published: (2018-07-01)

Efficacy and safety of pemetrexed maintenance therapy in advanced non-small-cell lung cancer: a review of phase III studies
by: O I Kit, et al.
Published: (2013-03-01)

Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study
by: Mark S. Walker, et al.
Published: (2017-08-01)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
by: Schuette W, et al.
Published: (2017-11-01)

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
by: Goyal Pankaj, et al.
Published: (2016-01-01)

Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung
by: Kim D. H., et al.
Published: (2015-06-01)

Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-small Cell Lung Cancer
by: Xingsheng HU, et al.
Published: (2012-10-01)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01)

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
by: Mubarak Nabil, et al.
Published: (2012-09-01)

Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer
by: Song X, et al.
Published: (2018-11-01)

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
by: Minami Seigo, et al.
Published: (2012-07-01)

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
by: Shao-Lun Lu, et al.
Published: (2016-08-01)

Predictive factors for long‐term responders of pemetrexed maintenance treatment in non‐small cell lung cancer
by: Joon‐Young Yoon, et al.
Published: (2019-04-01)

Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment
by: Yanyun Gao, et al.
Published: (2019-11-01)

Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
by: Lin L, et al.
Published: (2016-10-01)

A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/Cisplatin and Gemcitabine/Cisplatin as First-line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
by: Yan HUANG, et al.
Published: (2012-10-01)

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer
by: Andrea Cavazzoni, et al.
Published: (2020-03-01)

Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles
by: S. Visser, et al.
Published: (2019-05-01)

Correlation between MTHFR 677C > T polymorphism and response of pemetrexed-based chemotherapy in advanced NSCLC: A meta-analysis
by: Han Feng, et al.
Published: (2021-05-01)

GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins
by: Laurence Booth, et al.
Published: (2021-08-01)

Pemetrexed Hinders Translation Inhibition upon Low Glucose in Non-Small Cell Lung Cancer Cells
by: Marie Piecyk, et al.
Published: (2021-03-01)

Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment
by: Bonanno L, et al.
Published: (2016-06-01)

Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review
by: Jin-Yuan Shih, et al.
Published: (2020-09-01)

Quality of Life in Patients with NSCLC Receiving Maintenance Therapy
by: Achim Rittmeyer
Published: (2015-05-01)

Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin
by: Gulam Mohmad Rather, et al.
Published: (2021-02-01)

Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non‐small cell lung cancer
by: Motoko Tachihara, et al.
Published: (2020-09-01)

Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)
by: A. M. Lozhkina, et al.
Published: (2018-11-01)

Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study
by: Kengo Umehara, et al.
Published: (2020-10-01)

Effects of endostatin combined with pemetrexed and cisplatin on the levels of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma
by: Min Zhang, et al.
Published: (2017-10-01)

Effects of endostatin combined with pemetrexed and cisplatin on the levels of TNF-α, NSE, CEA, CA199, AFP and CYFRA21-1 in patients with advanced lung adenocarcinoma
by: Min Zhang, et al.
Published: (2017-10-01)

Etudes de stabilité de médicaments anticancéreux injectables : apports analytiques et pharmaceutiques
by: Respaud, Renaud
Published: (2011)

Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer
by: Beyrer, J., et al.
Published: (2022)

Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis
by: Xiao HQ, et al.
Published: (2016-03-01)

Investigation of Needs/Concerns of Teachers within an Induction Year Program
by: Beam, Pamela C.
Published: (2009)

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
by: Lan Shen, et al.
Published: (2020-05-01)

An Analysis of Induction-Year Agricultural Education Teachers' Attitude toward Teaching during the 2011-2012 School Year in Texas, Oklahoma, and New Mexico
by: Lawrence, Shannon 1980-
Published: (2013)

A long‐term survivor keeping in a complete response without treatment after pemetrexed maintenance therapy for advanced non‐squamous non‐small cell lung cancer
by: Makoto Furugen, et al.
Published: (2021-02-01)

Synthesis and Physicochemical Characterization of the Impurities of Pemetrexed Disodium, an Anticancer Drug
by: Olga Michalak, et al.
Published: (2015-05-01)

A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy  for Advanced Non-squamous Non-small Cell Lung Cancer
by: Hongyu DAI, et al.
Published: (2013-08-01)

Clinical observation of Alimta monotherapy in treatment of advanced non-small cell lung cancer
by: Haiyan WANG, et al.
Published: (2008-06-01)